Top-down treatment

Starting strong treatment such as a biologic, often with an immunosuppressant, soon after diagnosis, instead of trying milder medicines first.

Also called: top down, early biologic, early combined immunosuppression, top-down, topdown, early biologics, early advanced therapy, profile trial

Related words step-up treatment combination therapy infliximab

Topics Biologics and newer medicines Research Medicines

Questions people ask

What is 'top-down' treatment and is it better?

Top-down means starting strong treatment, such as a biologic plus an immunosuppressant, soon after diagnosis instead of trying milder medicines first ('step-up'). In the UK PROFILE trial of newly diagnosed adults, 79% on top-down treatment stayed in remission without steroids or surgery for a year, compared with 15% on step-up, with fewer flares and operations. Your team will weigh this up for your own situation.

Source

What is the difference between 'step-up' and 'top-down' treatment?

Step-up means starting with simpler treatments such as steroids and only moving on to stronger medicines if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunomodulator. The UK PROFILE trial found that, in newly diagnosed people with active Crohn's, top-down treatment led to far more steroid-free and surgery-free remission after a year, and fewer hospital stays and complications after five years. The 2025 BSG guideline now suggests early infliximab for moderate to severe Crohn's.

Sources

Can I have vaccines if I'm on azathioprine, biologics or other immunosuppressants?

Crohn's & Colitis UK says you should not have live vaccines, such as chickenpox, yellow fever or the children's nasal flu vaccine, while on an immunosuppressant. Non-live vaccines, such as the injected flu jab, COVID-19, pneumococcal and the Shingrix shingles vaccine, are safe. The NHS offers Shingrix to adults with a severely weakened immune system. Plan travel vaccines early with your IBD team, because some travel vaccines are live.

Sources

Where to read more

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease

Frontline Gastroenterology (via PMC) Guide Nov 2025 For professionals

A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.

Topics Medicines Surgery Monitoring

Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

The Lancet Gastroenterology & Hepatology Study Nov 2026 For professionals

Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.

Topics Biologics and newer medicines Research

Jargon explained top-down step-up disease modification stricturing penetrating disease

ISRCTN Registry

ISRCTN Tool Patients and professionals

A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.

Topics Research

Jargon explained trial registry study protocol ISRCTN number

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease (LIR!C)

The Lancet Gastroenterology & Hepatology Study Nov 2017 Patients and professionals

A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.

Topics Surgery Biologics and newer medicines Research

Jargon explained laparoscopic ileocaecal resection terminal ileum quality of life terminal ileitis

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Feb 2021 For professionals

European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.

Topics Children and young people Medicines Diet and nutrition Biologics and newer medicines

Jargon explained paediatric penetrating disease stricturing disease exclusive enteral nutrition anti-TNF immunomodulator therapeutic drug monitoring

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

Depression in adults

NHS Web page Jul 2023 For patients

The NHS guide to depression in adults: how it differs from feeling down for a few days, common signs such as low mood and losing interest in things, when to see a GP or get urgent help, and the main treatments, including talking therapies and antidepressants.

Topics Mental health

Jargon explained depression antidepressants

Search everything for "top-down treatment"